Last reviewed · How we verify
NCT03964259
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
Phase 1 trial testing Intravenous fluids in Lymphoma in 10 participants. Completed in 28 December 2022.
7 December 2022
Quick facts
| Lead sponsor | Virginia Commonwealth University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 10 |
| Start date | 2 October 2019 |
| Primary completion | 7 December 2022 |
| Estimated completion | 28 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Intravenous fluids — full drug profile →
Conditions studied
- Lymphoma — all drugs for Lymphoma →
- Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →
- Pediatric Cancer — all drugs for Pediatric Cancer →
- Pediatric ALL — all drugs for Pediatric ALL →
Sponsor
Virginia Commonwealth University
Who can join
Adults 1 to 17, any sex, with Lymphoma or Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine whether a reduced volume hydration regimen will lead to a shorter time to methotrexate clearance when compared to a standard intravenous (IV) hydration regimen.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Standard Versus Reduced Hydration to Improve Elimination of High-Dose Methotrexate in Pediatric Patients: A Controlled Crossover Trial.
Noda C, Gwaltney L, Sabo R, Lo M, et al · · 2025 · cited 1× · PMID 39868759 · DOI 10.1002/pbc.31566
Verify or expand the search:
- PubMed search for NCT03964259
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intravenous fluids
Trials testing the same drug.
- NCT07225205 — Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy · NA · recruiting
Other recruiting trials for Lymphoma
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
- NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting
Other Virginia Commonwealth University trials
Trials by the same sponsor.
- NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
- NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
- NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
- NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03964259 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
- Last refreshed: 13 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03964259.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing